European regulators recommend approval of Revolution Medicines' pancreatic cancer drug
The EU's medicines committee backed Rasonque, a Revolution Medicines treatment for pancreatic cancer, after a prior U.S. green light.
By Standard Topic. AI-generated from the reporting listed under Coverage. Published . Updated .
This story is no longer being updated. It reflects reporting up to .
What happened
European regulators have recommended approving Rasonque, a pancreatic cancer drug from Revolution Medicines, following an earlier green light from the FDA. The recommendation came alongside another pivotal approval endorsement this week, which covered Eli Lilly's obesity pill.
Why it matters
The recommendation moves the cancer drug closer to approval in Europe.
Coverage
- Lilly's obesity pill, RevMed's pancreatic cancer breakthrough among slew of CHMP endorsements in Europe (fiercepharma.com)
- RevMed's pancreatic cancer drug nears European approval (statnews.com)
More from Health
- Hackensack Meridian Health and Hunterdon Health agree to merge
- Roche signs $15 billion antibody-drug conjugate deal with Hansoh
- Putin's daughter predicts aging breakthroughs within 10 to 20 years
- Cardiologists urged to prescribe exercise for heart patients
- Pennsylvania measles outbreak tops 1,200 as CDC sends investigator
- AstraZeneca enlists Oracle to apply AI in drug trials